KEYTRUDA in advanced Renal Cell Carcinoma (aRCC)

KEYTRUDA® (pembrolizumab) in advanced Renal Cell Carcinoma (aRCC)

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA is indicated for:

Please consult the SmPC for further information before making any prescribing decisions.

KEYTRUDA reimbursement for 1L aRCC in the UK

KEYTRUDA and KISPLYX® (lenvatinib) reimbursement in the UK

NICE recommends pembrolizumab with lenvatinib as an option for untreated advanced renal cell carcinoma in adults, only if:3

  • their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria, and
  • nivolumab with ipilimumab would otherwise be offered

SMC accepts restricted* use of pembrolizumab in combination with lenvatinib for adults with advanced RCC, as 1L treatment.4

*SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule.4

KEYTRUDA and axitinib reimbursement in the UK

SMC accepts restricted* use of pembrolizumab in combination with axitinib, for the first-line treatment of advanced renal cell carcinoma in adults.5

*SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule.5

KEYTRUDA® (pembrolizumab) with KISPLYX® (lenvatinib)

KEYTRUDA® (pembrolizumab) with axitinib

Abbreviations

1L: first-line; NICE: National Institute for Health and Care Excellence; RCC: renal cell carcinoma; SMC: Scottish Medicines Consortium.

References

  1. KEYTRUDA (pembrolizumab) Summary of Product Characteristics.
  2. KISPLYX (lenvatinib) Summary of Product Characteristics.
  3. NICE Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma. Available at https://www.nice.org.uk/guidance/ta858/chapter/1-Recommendations.
  4. SMC Lenvatinib (KISPLYX). Available at https://www.scottishmedicines.org.uk/medicines-advice/lenvatinib-kisplyx-abb-smc2476/.
  5. SMC Pembrolizumab. Available at https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-full-smc2247/.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website